Two decades in review: Progress in the treatment of mCRPC

Brandon Bernard; Arun A. Azad; Kim N. Chi

Two decades in review: Progress in the treatment of mCRPC

Brandon Bernard, Arun A. Azad, Kim N. Chi

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Between the mid-1990s and now, median overall survival for men with metastatic castrate resistant prostate cancer (CRPC) starting on chemotherapy has risen from 1 year to almost 3 years. This review summarizes progress made over the last 2 decades in the systemic management of patients with CRPC and evolving treatment directions.

Original language	English
Pages (from-to)	18-23
Number of pages	6
Journal	Oncology Exchange
Volume	13
Issue number	3
Publication status	Published - 1 Aug 2014
Externally published	Yes

Keywords

Androgen deprivation therapy
Androgen receptor antagonist
Bone-targeted therapy
Chemotherapy
Immunotherapy
Metastatic castration-resistant prostate cancer
Predictive biomarker
Radiopharmaceutical

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{805a9831f2144a259253d40daf44867f,

title = "Two decades in review: Progress in the treatment of mCRPC",

abstract = "Between the mid-1990s and now, median overall survival for men with metastatic castrate resistant prostate cancer (CRPC) starting on chemotherapy has risen from 1 year to almost 3 years. This review summarizes progress made over the last 2 decades in the systemic management of patients with CRPC and evolving treatment directions.",

keywords = "Androgen deprivation therapy, Androgen receptor antagonist, Bone-targeted therapy, Chemotherapy, Immunotherapy, Metastatic castration-resistant prostate cancer, Predictive biomarker, Radiopharmaceutical",

author = "Brandon Bernard and Azad, {Arun A.} and Chi, {Kim N.}",

year = "2014",

month = aug,

day = "1",

language = "English",

volume = "13",

pages = "18--23",

journal = "Oncology Exchange",

issn = "1705-2394",

publisher = "Parkhurst Publishing",

number = "3",

}

TY - JOUR

T1 - Two decades in review

T2 - Progress in the treatment of mCRPC

AU - Bernard, Brandon

AU - Azad, Arun A.

AU - Chi, Kim N.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Between the mid-1990s and now, median overall survival for men with metastatic castrate resistant prostate cancer (CRPC) starting on chemotherapy has risen from 1 year to almost 3 years. This review summarizes progress made over the last 2 decades in the systemic management of patients with CRPC and evolving treatment directions.

AB - Between the mid-1990s and now, median overall survival for men with metastatic castrate resistant prostate cancer (CRPC) starting on chemotherapy has risen from 1 year to almost 3 years. This review summarizes progress made over the last 2 decades in the systemic management of patients with CRPC and evolving treatment directions.

KW - Androgen deprivation therapy

KW - Androgen receptor antagonist

KW - Bone-targeted therapy

KW - Chemotherapy

KW - Immunotherapy

KW - Metastatic castration-resistant prostate cancer

KW - Predictive biomarker

KW - Radiopharmaceutical

UR - http://www.scopus.com/inward/record.url?scp=85043216743&partnerID=8YFLogxK

M3 - Article

SN - 1705-2394

VL - 13

SP - 18

EP - 23

JO - Oncology Exchange

JF - Oncology Exchange

IS - 3

ER -

Two decades in review: Progress in the treatment of mCRPC

Abstract

Keywords

UN SDGs

Other files and links

Cite this